STOCK TITAN

Sigyn Therapeutics Inc - SIGY STOCK NEWS

Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.

Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a San Diego-based innovator developing blood purification technologies to combat life-threatening inflammatory conditions. This page serves as the definitive source for tracking SIGY's progress in advancing Sigyn Therapy™ and its complementary platforms targeting chemotherapy optimization and immunotherapy enhancement.

Investors and medical professionals will find timely updates on clinical milestones, regulatory developments, and strategic initiatives. Key focus areas include first-in-human studies for endotoxemia treatment, advancements in ImmunePrep™ antibody optimization, and progress toward Nasdaq listing requirements through recent corporate restructuring.

Our curated news stream covers essential updates including trial protocol finalizations, technology validation results, partnership announcements, and financial disclosures. All content is vetted for accuracy and relevance to SIGY's mission of addressing unmet needs in sepsis management, cancer care, and infectious disease treatment.

Bookmark this page for streamlined access to SIGY's evolving story in medical technology. Check regularly for developments that could influence both patient outcomes and long-term corporate valuation in this emerging therapeutic sector.

Rhea-AI Summary
Sigyn Therapeutics, Inc. announces CEO Jim Joyce's live presentation at the Emerging Growth Conference to update on Sigyn TherapyTM and new cancer treatment products. The presentation will focus on a novel blood purification technology for life-threatening conditions and products to enhance chemotherapy and immunotherapy benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Sigyn Therapeutics, Inc. filed its Form 10-K annual report with the SEC for 2023, introduced new therapeutic candidates, and prepared for first-in-human clinical studies. The company reported a loss from operations of $2.5 million and a net loss of $4.1 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sigyn Therapeutics, Inc. announced a 1-for-40 reverse stock split, with the common stock trading under the ticker symbol 'SIGYD' for 20 days and then reverting to 'SIGY' on February 29, 2024. The Company also reported 1,221,043 common shares issued and outstanding as of January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1900%
Tags
Rhea-AI Summary
Sigyn Therapeutics, Inc. announced a 1-for-40 reverse split of its common stock to increase the market price per share and gain compliance with the minimum bid listing requirement of The Nasdaq Capital Market. The reverse split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
-
Rhea-AI Summary
Sigyn Therapeutics, Inc. (SIGY) announces release of shareholder letter by Chairman and CEO, Jim Joyce, detailing the company's development-stage medical technology and prospects for its therapies. The letter provides an update on proposed underwritten financing and discusses the development of Sigyn TherapyTM, ImmunePrepTM, ChemoPrepTM, and ChemoPureTM platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sigyn Therapeutics, Inc. (SIGY) appoints Jerry DeCiccio, CPA, MBA, as Chief Financial Officer, bringing over 40 years of financial industry experience to the Company. Mr. DeCiccio has held executive roles at publicly traded companies, including Intech Electromechanical, GTC Telecom, Incomnet Communications, and Cerebain Biotech Corp. He has also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc., and Newport Corp. Mr. DeCiccio's appointment follows the tenure of Jeremy Farrell, who was previously appointed CFO in March of 2022. The company expresses its appreciation for Farrell's service and looks forward to focusing on the clinical advancement of Sigyn Therapy and unlocking the value of its therapeutic pipeline with Jerry DeCiccio on board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.21%
Tags
management
Rhea-AI Summary
Sigyn Therapeutics, Inc. (OTCQB: SIGY) announces financial results for Q3 2023, highlighting plans for first-in-human studies of Sigyn TherapyTM and pipeline technologies to enhance cancer therapies. The Company aims to address end-stage renal disease (ESRD) patients with endotoxemia, with a focus on safety. Financially, Sigyn had a loss from operations of approximately $642,814, and a net loss of approximately $905,726 for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sigyn Therapeutics submits a Patent Cooperation Treaty (PCT) application to enhance chemotherapy delivery and reduce toxicity. The company is developing ChemoPrepTM and ChemoPureTM technologies to increase tumor-site saturation of chemotherapy agents with reduced doses. This may improve treatment outcomes, alleviate supply chain issues, and enhance patient quality of life. No concrete business takes affecting stock price are mentioned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sigyn Therapeutics, Inc. announces online presentation at Emerging Growth Conference and in-person presentation at NIBA Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences acquisition
Rhea-AI Summary
Sigyn Therapeutics, Inc. (SIGY) announces financial results for Q2 2023, including a focus on first-in-human studies of Sigyn TherapyTM and the introduction of ImmunePrepTM, a platform designed to enhance the delivery of immunotherapeutic antibodies. The company reported a loss from operations of approximately $574,009 and a net loss of approximately $723,124 for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
Sigyn Therapeutics Inc

OTC:SIGY

SIGY Rankings

SIGY Stock Data

6.58M
949.02k
40.89%
6.1%
Biotechnology
Healthcare
Link
United States
San Diego